Clinical trial
28-Day Study of Testosterone Co-administered With Dutasteride in Hypogonadal Men
NCT00398580 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00398580 |
|---|---|
| Title | 28-Day Study of Testosterone Co-administered With Dutasteride in Hypogonadal Men |
| Official title | A Phase II, 28-Day, Randomized, Parallel-Group, Open-Label Study Evaluating the Efficacy and Safety of Twice Daily Oral Doses of Testosterone (150-400mg) Co-administered With 0.25mg Dutasteride Compared With 400mg Testosterone Alone and 0.25mg Dutasteride Alone in the Treatment of Hypogonadism |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hypogonadism, Male |
| Intervention type | Drug |
| Interventions | Nanomilled testosterone, Nanomilled dutasteride, commercially available dutasteride |
| Enrollment | 43 |
| Start date | Oct 1, 2006 |
| Primary completion | Oct 1, 2007 |
| Completion | Oct 1, 2007 |
| First posted | Nov 10, 2006 |
| Last update posted | May 30, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: